Table 3.
Baseline demographic and treatment characteristics.
| Intervention group (n = 70) | Control group (n = 72) | p | |
|---|---|---|---|
| Age (years) | 52.5 (9.0) | 53.2 (8.6) | 0.550 |
| Education level (n (%)) | |||
| High | 34 (48.6) | 30 (41.7) | |
| Middle | 36 (51.4) | 42 (58.3) | |
| Low | 0 (0) | 0 (0) | 0.451 |
| Physical fitness (VO2peak in ml/min/kg) | 23.5 (4.6) | 24.8 (6.1) | 0.175 |
| Body mass index (BMI) | 29.6 (5.8) | 28.3 (5.4) | 0.197 |
| Menopausal status (n (%)) | |||
| Pre/peri | 9 (12.9) | 7 (9.7) | |
| Post | 61 (87.1) | 65 (90.3) | 0.575 |
| Age of menopause (years) | 48.0 (6.4) | 47.7 (5.4) | 0.917 |
| Time since diagnosis (years)* | 3.1 (0.7) | 3.1 (0.6) | 1.000 |
| Tumor grade (n (%)) | |||
| I | 11 (15.7) | 5 (6.9) | |
| II | 28 (40.0) | 31 (43.1) | |
| III | 24 (34.3) | 28 (38.9) | |
| Unknown | 7 (10.0) | 8 (11.1) | 0.447 |
| Surgery (n (%)) | 70 (1 0 0) | 72 (1 0 0) | 1.000 |
| Chemotherapy timing (n (%)) | |||
| Neoadjuvant | 31 (44.3) | 34 (47.2) | |
| Adjuvant | 37 (52.9) | 36 (50.0) | |
| Both | 1 (1.4) | 1 (1.4) | |
| Unknown | 1 (1.4) | 1 (1.4) | 0.980 |
| Time since completion chemotherapy (years)* | 2.7 (0.7) | 2.7 (0.6) | 0.625 |
| Radiation (n (%)) | |||
| Yes | 54 (77.1) | 55 (76.4) | |
| No | 16 (22.9) | 17 (23.6) | 0.964 |
| Targeted therapy (n (%)) | |||
| Yes | 16 (22.9) | 15 (20.8) | |
| No | 54 (77.1) | 56 (77.8) | |
| Unknown | 1 (1.4) | 0.559 | |
| Endocrine therapy (n (%)) | |||
| Yes | 44 (62.9) | 45 (62.5) | |
| No | 26 (37.1) | 27 (37.5) | 0.914 |
| Medication use (n (%)) | |||
| Cardiovascular | 14 (20.0) | 14 (19.4) | 0.967 |
| Anti-diabetic | 1 (1.4) | 1 (1.4) | 0.992 |
| Psychotropic | 21 (30.0) | 12 (16.7) | 0.040* |
| Pain medication | 11 (15.7) | 12 (16.7) | 0.971 |
Values indicate mean (SD) unless indicated otherwise. P values indicate overall group differences.
*For time since diagnosis, average years was based on 63 intervention patients and 67 control patients. For time since completion chemotherapy, average years was based on 65 intervention patients and 62 control patients.